AL
ALSEN.PA Sensorion SA
- Market cap
- EUR 91.1M
- P/E
- -
- P/B
- 1.12x
- ROE
- -101.5%
- Dividend yield
- -
- Fundamental score
- 1.0/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALSEN.PA undervalued?
Graham numberThe Graham number of Sensorion SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sensorion SA fundamental analysis
3 of 11 checks passedROE 0/2
The stock's ROE indicates a negative return (-70.61%) on shareholders' equity, suggesting poor financial performance.
ROA 0/2
The stock's ROA (-60.52%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.
PBV 1/2
The stock's PBV ratio (1.93x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.
DER 2/2
The stock has a minimal amount of debt (18%) relative to its ownership, showcasing a strong financial position and lower risk for investors.
Revenue Growth 0/2
Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.
Net Profit Growth 0/2
This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.
Assets Growth 0/2
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.
Graham Number 1/1
The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.
Dividend Growth 0/2
The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.
Dividend 0/2
Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.
Buffet Intrinsic Value 0/1
The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Sensorion SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sensorion SA
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a s…
Full company profileSensorion SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sensorion SA annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 17.5K | 1.93M | 2.23M | 2.46M | 2.35M | 4.26M | 4.93M | 5.70M | 6.65M | 0.00 | - |
| Gross Profit | -6.76M | 1.55M | 1.88M | 2.15M | 1.94M | 3.75M | 4.16M | 3.79M | 6.65M | -1.36M | -3.50M |
| Operating Income | -9.11M | -9.61M | -12.3M | -13.3M | -11.3M | -19.4M | -28.1M | -22.3M | -28.4M | -36.6M | -96.4M |
| EBITDA | -8.72M | -9.29M | -11.9M | -10.7M | -10.3M | -17.5M | -22.4M | -20.6M | -28.2M | -36.3M | -92.9M |
| Net Income | -7.41M | -9.69M | -12.4M | -12.1M | -8.98M | -15.1M | -23.2M | -22.1M | -26.0M | -29.4M | -82.8M |
| EPS | -54 | -67 | -54 | -0.65 | -7.39 | -9.50 | -15 | -8.27 | -4.57 | -4.89 | -8.03 |
| Balance Sheet | |||||||||||
| Total Assets | 11.9M | 11.2M | 9.47M | 38.1M | 67.9M | 59.0M | 38.9M | 46.5M | 89.3M | 57.9M | 101M |
| Total Liabilities | 3.26M | 3.84M | 5.96M | 24.9M | 9.52M | 15.0M | 17.1M | 13.2M | 17.1M | 13.4M | 19.2M |
| Shareholders' Equity | 8.59M | 7.32M | 3.51M | 13.2M | 58.3M | 44.0M | 21.9M | 33.3M | 72.1M | 44.5M | 81.6M |
| Cash & Short-term Investments | 8.53M | 7.59M | 2.71M | 30.4M | 62.2M | 50.0M | 26.2M | 37.0M | 77.0M | 47.5M | 88.5M |
| Total Debt | 975K | 374K | 10.9K | 21.0M | 3.88M | 3.99M | 3.76M | 2.87M | 2.20M | 1.28M | 3.20M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.19M | -7.78M | -12.2M | -14.2M | -5.31M | -10.8M | -21.4M | -21.1M | -21.3M | -27.4M | -71.0M |
| Capital Expenditure | 533K | 166K | 14.6K | 74.5K | 165K | 1.04M | 1.51M | 869K | 1.12M | 253K | 1.04M |
| Free Cash Flow | -7.73M | -7.95M | -12.3M | -14.2M | -5.48M | -11.8M | -22.9M | -21.9M | -22.5M | -27.6M | -72.1M |
| Ratios | |||||||||||
| ROE | -86.3% | -132.3% | -351.8% | -91.6% | -15.4% | -34.4% | -106.1% | -66.3% | -36.0% | -66.2% | -101.5% |
| ROA | -62.5% | -86.8% | -130.4% | -31.8% | -13.2% | -25.6% | -59.6% | -47.4% | -29.1% | -50.8% | -82.2% |
| Net Profit Margin | -42,357.0% | -500.7% | -553.7% | -492.4% | -381.7% | -355.0% | -470.4% | -387.2% | -390.4% | - | - |
| Debt to Equity | 0.11x | 0.05x | 0.00x | 1.59x | 0.07x | 0.09x | 0.17x | 0.09x | 0.03x | 0.03x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sensorion SA dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | EUR 124K | 0.08 | - |
| 2020 | EUR 97.6K | 0.08 | - |
| 2019 | - | - | - |
| 2018 | EUR 8.01M | 35 | - |
| 2017 | EUR 6.70M | 47 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:50 on Sep 15, 2026.
Who owns Sensorion SA
- Insiders 34.76%
- Institutions 32.64%
- Public & others 32.60%
- Shares outstanding 10.3M
- Free float 3.72M
Sensorion SA company profile
- Company name
- Sensorion SA
- Ticker
- ALSEN.PA
- ISIN
- FR001401A9Z0
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 66
- Fiscal year end
- December
- Address
- 375, rue du Professeur Joseph Blayac, Montpellier, France, 34080
- Phone
- 33 4 67 20 77 30
- Website
- sensorion.com
About Sensorion SA
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.
Sensorion SA management
7- Mr. Frederic Chereau M.B.A.Chief Executive Officer · born 1967
- Mr. Louis J. Arcudi III, M.B.A.Chief Financial Officer · born 1961
- Mr. Bernd SchmidtChief Technical Officer
- Ms. Christine Le BecHead of CMC Gene Therapy
- Ms. Stephanie FilipeHead of Business Operations & Portfolio Management
- Mr. Laurent DesireHead of Preclinical Development
- Ms. Rachel CooperHead of Audiology